sunny.png
Tuesday January 28th, 2020 10:55AM

Drugs make headway against lung, breast, prostate cancers

By The Associated Press

CHICAGO (AP) — Newer drugs are substantially improving the chances of survival for some people with hard-to-treat forms of lung, breast and prostate cancer, doctors reported at the world's largest cancer conference.

Among those who have benefited is Roszell Mack Jr., who at age 87 is still able to work at a Lexington, Kentucky, horse farm, nine years after being diagnosed with lung cancer that had spread to his bones and lymph nodes.

"I go in every day, I'm the first one there," said Mack, who helped test Merck's Keytruda, a therapy that helps the immune system identify and fight cancer. "I'm feeling well and I have a good quality of life."

The downside: Many of these drugs cost $100,000 or more a year, although what patients pay out of pocket varies depending on insurance, income and other criteria.

The results were featured Saturday and Sunday at the American Society of Clinical Oncology conference in Chicago and some were published by the New England Journal of Medicine. Companies that make the drugs sponsored the studies, and some study leaders have financial ties.

Here are some highlights:

LUNG CANCER

Immunotherapy drugs such as Keytruda have transformed the treatment of many types of cancer, but they're still fairly new and don't help most patients. The longest study yet of Keytruda in patients with advanced lung cancer found that 23% of those who got the drug as part of their initial therapy survived at least five years, whereas 16% of those who tried other treatments first did.

In the past, only about 5% of such patients lived that long.

"I'm a big believer that it's not just about duration of life, quality of life is important," said Dr. Leora Horn, of the Vanderbilt-Ingram Cancer Center in Nashville, Tennessee. She enrolled Mack in the 550-person study.

Mack said he had manageable side effects — mostly some awful itching — after starting on Keytruda four years ago. He went off it last winter and scans showed no active cancer; he and his doctor hope it's in remission.

Last year, a smaller study reported five-year survival rates of 16% for similar patients given another immunotherapy, Opdivo.

"From both studies we're getting a similar message: When these drugs work, they can have a really durable effect," Horn said.

BREAST CANCER

The risk of this rises with age, but about 48,000 cases each year in the U.S. are in women under age 50. About 70% are "hormone-positive, HER2-negative" — that is, the cancer's growth is fueled by estrogen or progesterone and not by the gene that the drug Herceptin targets.

In a study of 672 women with such cancers that had spread or were very advanced, adding the Novartis drug Kisqali to the usual hormone blockers as initial therapy helped more than hormone therapy alone.

After 3 1/2 years, 70% of women on Kisqali were alive, compared to 46% of the rest. Side effects were more common with Kisqali.

This is the first time any treatment has boosted survival beyond what hormone blockers do for such patients.

PROSTATE

The options keep expanding for men with prostate cancer that has spread beyond the gland. Standard treatment is drugs that block the male hormone testosterone, which helps these cancers grow, plus chemotherapy or a newer drug called Zytiga.

Now, two other drugs have proven able to extend survival when used like chemo or Zytiga in men who were getting usual hormone therapy and still being helped by it.

One study tested Xtandi, sold by Pfizer and Astellas Pharma Inc., in 1,125 men, half of whom also were getting chemo. After three years, 80% of those given Xtandi plus standard treatments were alive, compared to 72% of men given the other treatments alone.

The other study involved 1,052 men who were given hormone therapy with or without the Janssen drug Erleada. After two years, survival was 82% among those on Erleada and 74% among those who weren't.

Men now have a choice of four drugs that give similar benefits, and no studies yet have compared them against each other, said Dr. Ethan Basch, a prostate specialist at the University of North Carolina's Lineberger Comprehensive Cancer Center who has no financial ties to any drugmakers.

Cost and side effects may help patients decide, he said. Chemo can cause numbness and tingling in the hands and feet and may not be good for men with diabetes who already are at higher risk for this problem. Zytiga must be taken with a steroid; Xtandi and Erleada can cause falling and fainting.

Chemo has more side effects but costs much less and requires only four to six intravenous treatments. The other three drugs are pills that cost more than $10,000 a month and are taken indefinitely.

"I have patients who refuse to take these drugs because of cost," Basch said. "Patients have more choice, but it isn't clear more benefit is being provided" beyond what chemo gives, he said.

___

Marilynn Marchione can be followed at http://twitter.com/MMarchioneAP

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education. The AP is solely responsible for all content.

  • Associated Categories: Associated Press (AP), AP National News, AP Online National News, Top General short headlines, AP Health, AP Health - Men's Health, AP Health - Women's health
© Copyright 2020 AccessWDUN.com
All rights reserved. This material may not be published, broadcast, rewritten, or redistributed without permission.
German government wobbles after Social Democrat leader quits
German Chancellor Angela Merkel has vowed to continue with her government after the leader of the center-left Social Democrats, a junior partner in the coalition, resigned following a series of disappointing election results
12:23PM ( 36 seconds ago )
Drugs make headway against lung, breast, prostate cancers
Newer drugs are improving survival for some people with hard-to-treat forms of cancer
12:14PM ( 9 minutes ago )
The Latest: Nadal joins Federer in French Open quarterfinals
Defending champion Rafael Nadal is through to the French Open quarterfinals after beating unseeded Argentine Juan Ignacio Londero 6-2, 6-3, 6-3 in their first ever meeting
12:05PM ( 18 minutes ago )
Associated Press (AP)
Judge says Missouri clinic can keep providing abortions
A Missouri judge issued an order Friday ensuring the state's only abortion clinic can continue providing the service, acting just hours before the St. Louis Planned Parenthood facility's license was set to expire
8:15AM ( 1 day ago )
Judge says Missouri clinic can keep providing abortions
A Missouri judge issued an order Friday ensuring the state's only abortion clinic can continue providing the service, acting just hours before the St. Louis Planned Parenthood facility's license was set to expire
6:53PM ( 1 day ago )
Judge's order means Missouri clinic can keep doing abortions
A Missouri judge issued an order Friday ensuring the state's only abortion clinic can continue providing the service, acting just hours before the St. Louis Planned Parenthood facility's license was set to expire
2:39PM ( 1 day ago )
AP Health
US cancer death rate hits milestone: 25 years of decline
The U.S. cancer death rate has now been falling for 25 years _ an important milestone in the overall decline
4:12PM ( 4 months ago )
AP Health - Men's Health
Judge considering Missouri abortion clinic license case
A St. Louis judge is deciding whether to grant an order that would allow Missouri's only abortion clinic to keep its abortion license past Friday
6:29PM ( 2 days ago )
Girl believed to be tiniest newborn weighed as much as apple
Baby born in San Diego weighing about same as an apple is believed to be world's tiniest surviving newborn
9:57PM ( 3 days ago )
Size of an apple: Girl becomes tiniest newborn to survive
Baby born in San Diego weighing about same as an apple is believed to be world's tiniest surviving newborn
8:44PM ( 3 days ago )
AP Health - Women's health
German government wobbles after Social Democrat leader quits
German Chancellor Angela Merkel has vowed to continue with her government after the leader of the center-left Social Democrats, a junior partner in the coalition, resigned following a series of disappointing election results
12:23PM ( 38 seconds ago )
The Latest: Nadal joins Federer in French Open quarterfinals
Defending champion Rafael Nadal is through to the French Open quarterfinals after beating unseeded Argentine Juan Ignacio Londero 6-2, 6-3, 6-3 in their first ever meeting
12:05PM ( 18 minutes ago )
Pompeo says US ready to talk to Iran with 'no preconditions'
Secretary of State Mike Pompeo says the Trump administration is ready for unconditional discussions with Iran in an effort to ease rising tensions that have sparked fears of conflict
12:05PM ( 19 minutes ago )
A diminished 'Godzilla' still bests 'Rocketman,' 'Ma'
"Godzilla: King of the Monsters" was brought down to size at the weekend box office but was still easily No. 1, while the Elton John biopic "Rocketman" and the Octavia Spencer-led horror film "Ma" got off to strong starts
12:02PM ( 21 minutes ago )
Virginia Beach attacker notified boss of plans to leave job
Officials in Virginia Beach say the gunman who opened fire inside a city government building had notified a superior of his intention to leave his job
11:55AM ( 28 minutes ago )